Longevica Therapeutics Appoints Ex-Genentech Biotech Veteran Dr. Prasun Mishra as CEO to Advance World's Largest $13 Million Mammalian Longevity Study Toward Clinical Development
Longevica Therapeutics, Inc. ("Longevica"), a preclinical biotechnology company pioneering target discovery and small-molecule therapeutics from full-lifespan mammalian geroscience, today announced the appointment of biopharmaceutical executive Dr. Prasun Mishra as Chief Executive Officer and member of its Board of Directors. The appointment marks Longevica's strategic transition from foundational discovery to systematic drug development, accelerating the translation of its proprietary mammalian longevity dataset into clinical pipeline candidates.
